In 2025, Type 2 Diabetes has emerged as the largest therapeutic segment, accounting for approximately 78% of the total insulin market size. While Type 1 patients have a lifelong, absolute requirement for insulin, the global rise in obesity and sedentary lifestyles has led to a massive increase in insulin-dependent Type 2 cases. This demographic shift is driving a high volume of demand for both...